GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

The following is a summary of “Sodium-glucose cotransporter 2 inhibitors and glaucoma in patients with type 2 diabetes,” ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

MONDAY, Nov. 11, 2024 (HealthDay News) -- The weight-loss drug Ozempic can help reduce stroke patients’ risk of a heart ...

Stroke was the fourth leading cause of death in the US last year, accounting for 162,600 deaths, according to preliminary data.

Empagliflozin, or Empa, is a medication often used to help people with type 2 diabetes manage their blood sugar. Now, ...

The medications include GLP-1 drugs such as Ozempic from Novo Nordisk and Trulicity from Eli Lilly, and SGLT2 drugs such as ...

New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

The Prescription Drug User Fee Act date refers to the deadline set by the FDA for reviewing a NDA or Biologics License Application.

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.